Fierce Healthcare March 20, 2023
By Robert King

States have been grappling with rising Medicaid drug costs for the past several years. A new report from the Medicaid and CHIP Payment and Access Commission gives some recommendations on how to handle the issue. (Getty/Charles Wollertz)

Congress should give states the power to not pay full price under Medicaid for drugs approved under the Food and Drug Administration’s accelerated approval pathway, a key advisory panel said.

The Medicaid and CHIP Payment and Access Commission (MACPAC) released proposals for Congress as part of its March report last week (PDF). One of the key recommendations is to limit state coverage under Medicaid of drugs cleared via accelerated approval that have not completed a confirmatory trial. The recommendation is...

Today's Sponsors

Upfront Healthcare

Today's Sponsor


Topics: Congress / White House, Govt Agencies, Insurance, Medicaid, States, Survey / Study, Trends
Medicaid disenrollments as a percentage of total completed renewals in 10 states
South Dakota expands Medicaid coverage: 4 CMS updates
Oklahoma awards Medicaid contracts to Aetna, Centene, Humana
Consumer health data: A risk-based approach to digital privacy
5 states reviewing healthcare M&A oversight

Share This Article